Search

Displaying results 1741 - 1750 of 5758 in total
  1. Drug

    Cyclothiazide

    go.drugbank.com/drugs/DB00606
    Approved

    As a diuretic, cyclothiazide inhibits active chloride reabsorption at the early distal tubule via the Na-Cl cotransporter, resulting in an increase in the excretion of sodium, chloride, and water.

  2. Drug

    Rimegepant

    go.drugbank.com/drugs/DB12457
    ApprovedInvestigational

    [A189207] Antagonism of the CGRP pathway has become an attractive target for migraine therapy as, unlike the triptans, oral CGRP antagonists have no observed vasoconstrictive properties and are therefore

    Categories: P-glycoprotein substrates, Cytochrome P-450 Substrates
  3. Drug

    Mirabegron

    go.drugbank.com/drugs/DB08893
    ApprovedInvestigational

    [L32853] Mirabegron is also used in other jurisdictions across the globe, including Canada,[L32925] the EU,[L32945] and Japan.[A7469]

    Categories: P-glycoprotein inhibitors, P-glycoprotein substrates
  4. Drug

    Thymalfasin

    go.drugbank.com/drugs/DB04900
    Investigational

    Thymalfasin is a chemically synthesized version of thymosin alpha 1 that is identical to human thymosin alpha 1. Thymosin alpha 1 is an acetylated polypeptide. Thymosin alpha 1 is now approved in 35 developing countries for the treatment...

  5. Drug

    Glasdegib

    go.drugbank.com/drugs/DB11978
    ApprovedInvestigational

    Glasdegib, also known as PF-04449913, is a small-molecule hedgehog signaling inhibitor selected under the group of benzimidazoles. … This analysis concluded that the presence of p-cyano ureas presented good physicochemical and pharmacokinetic properties from which glasdegib was developed.

    Categories: Cytochrome P-450 Substrates, P-glycoprotein inhibitors
  6. Drug

    4-Hydroxytestosterone

    go.drugbank.com/drugs/DB01485
    IllicitInvestigational

    It is an anabolic steroid with no therapeutic indications, which is prohibited from use in sports by the World Anti-Doping Agency. … [A14385] Like formestane, 4-hydroxytesterone has been patented for use in decreasing estrogen production in the body, but no such indication currently exists. 4-Hydroxytestosterone was first patented in

  7. Drug

    Migalastat

    go.drugbank.com/drugs/DB05018
    ApprovedInvestigational

    Fabry disease is a rare, progressive genetic disorder characterized by a defective GLA gene that causes a deficiency in the enzyme alpha-Galactosidase A (alpha-Gal A). This enzyme is responsible for breaking down glycosphingolipid substr...

  8. Drug

    Hu-rhEGF-rP64k/Mont

    go.drugbank.com/drugs/DB15781
    Investigational

    Hu-rhEGF-rP64k/Mont is a therapeutic vaccine composed by an antigen (recombinant human EGF (rhEGF) chemically conjugated to recombinant P64K (rP64K)) and an adjuvant (Montanide ISA51VG) being investigated

    Synonyms: Hu-rhEGF-rP64k/Mont
  9. Drug

    AZD0947

    go.drugbank.com/drugs/DB04848
    Experimental

    As of March 2003, the drug was in phase II trials; however, as of October 2004, it no longer appeared on the company’s development pipeline.

  10. Drug

    Garadacimab

    go.drugbank.com/drugs/DB15629
    Approved

    [L53283,A273998] Garadacimab received its first approval in Australia and the UK in January 2025, and has since been approved in a number of other jurisdictions, including the EU and Japan.